Subscribe
takeda-us
Takeda Oncology offices based in Boston, Massachusetts
25 March 2015Americas

Takeda signs deal with ImmunoGen to develop cancer drugs

Massachusetts-based biotechnology company ImmunoGen has granted pharmaceutical company Takeda exclusive rights to use its antibody-drug conjugate (ADC) technology to develop and commercialise cancer drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
ImmunoGen cancer treatment application gets another chance
29 March 2022   ImmunoGen has been given the go-ahead to revive its patent application for a cancer treatment dosage following a Federal Circuit ruling on Friday.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
ImmunoGen cancer treatment application gets another chance
29 March 2022   ImmunoGen has been given the go-ahead to revive its patent application for a cancer treatment dosage following a Federal Circuit ruling on Friday.

More on this story

Big Pharma
ImmunoGen cancer treatment application gets another chance
29 March 2022   ImmunoGen has been given the go-ahead to revive its patent application for a cancer treatment dosage following a Federal Circuit ruling on Friday.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB